Zhitong Finance APP was informed that Xiaomo released a report saying,Alibaba Health(00241) recently announced to the parent companyAlibaba(09988) acquired Tmall drug sales platform. The target business generated a total transaction amount of approximately 9.575 billion yuan in the year ended the end of March last year, and the total transaction consideration was 8.075 billion yuan, which is equivalent to approximately 0.76 times of the total transaction amount of the valuation/platform.The bank added that it has a positive sense of the above-mentioned transactions, and even said that the timing of injecting drug business is good, which will help Ali Health develop an online prescription drug sales platform in the mainland, and further strengthen Ali Health's position as the flagship platform of Alibaba's great health. It is believed that it will have a positive stimulating effect on Ali Health's stock price in the short term. The bank said it maintained its "overweight" rating with a price target of HK$10.7.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments